



INDO BORAX & CHEMICALS LTD.

Regd. Office: 302, 3rd Floor Link Rose Building, Linking Road, Santacruz (West), Mumbai - 400054, India.

Ph.: 022 26489142 / 47 / 48 • Fax No. 022-26489143 • CIN : L24100MH1980PLC023177

Email : info@indoborax.com • Website : www.indoborax.com

Date: January 23, 2026

BSE Limited The Corporate Relations Department, 25 th Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Stock Code – 524342	National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051 Stock Code - INDOBORAX
--	--

Dear Sir/Madam,

Sub: Intimation of the date of completion of the transactions contemplated in Share Purchase Agreement dated December 15, 2025

Ref: Disclosure under Regulations 30 and 30A read with paragraph A(5) and A(5A) of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time (“SEBI LODR Regulations”) read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (“SEBI Master Circular”)

We refer to our earlier disclosure dated December 15, 2025 regarding the execution of share purchase agreement dated December 15, 2025 by and amongst Mr. Sajal Sushilkumar Jain, Mrs. Sreelekha Sajal Jain, Mr. Saumya Sajal Jain, Mrs. Pranika Saumya Jain, Sajal Sushilkumar Jain HUF, Mrs. Shubhra Jain Sivaradjou (collectively, the “Sellers”), Zenrock Chemicals Private Limited, India Special Assets Fund III, ISAF III Onshore Fund and Special Situation India Fund (the “SPA”).

Pursuant to Regulation 30 read with Regulation 30A and Schedule III Part A Para A of the SEBI LODR Regulations, we wish to inform you that the Company has, on January 23, 2026, received an intimation from the Sellers, who are members of the promoter/ promoter group of the Company, that the parties to the SPA have, on January 22, 2026, executed a letter agreement to set out the date of completion of the transactions contemplated under the SPA as January 23, 2026 (the “SPA Letter Agreement”). The Company is not a party to the SPA Letter Agreement.

Details of the SPA Letter Agreement, as required under the SEBI LODR Regulations read with the SEBI Master Circular, is enclosed herewith as “Annexure I”.



INDO BORAX & CHEMICALS LTD.

Regd. Office: 302, 3rd Floor Link Rose Building, Linking Road, Santacruz (West), Mumbai - 400054, India.

Ph.: 022 26489142 / 47 / 48 • Fax No. 022-26489143 • CIN : L24100MH1980PLC023177

Email : info@indoborax.com • Website : www.indoborax.com

You are kindly requested to take note of the above.

Thanking you,

Yours faithfully,

For Indo Borax & Chemicals Limited

Pravin Chavan
Company Secretary & Compliance Officer

Enc.: As Above



ANNEXURE I

Disclosure under Regulations 30A read with Clause 5A of Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

S. No.	Particulars	Details
1.	If the listed entity is a party to the agreement: Details of the counterparties (including name and relationship with the listed entity)	No, the listed entity, i.e. Indo Borax & Chemicals Limited (" Company ") is not a party to the letter agreement to the share purchase agreement dated December 15, 2025 (" SPA ") among Mr. Sajal Sushilkumar Jain, Mrs. Sreelekha Sajal Jain, Mr. Saumya Sajal Jain, Mrs. Pranika Saumya Jain, Sajal Sushilkumar Jain HUF, Mrs. Shubhra Jain Sivaradjou (together, the " Sellers "), Zenrock Chemicals Private Limited, India Special Assets Fund III, ISAF III Onshore Fund and Special Situation India Fund (" Purchasers " and together with Sellers, " SPA Parties "). Such letter agreement to the SPA, the " SPA Letter Agreement ".
2.	If listed entity is not a party to the agreement: i. Name of the party/ies entering into such an agreement and the relationship with the listed entity ii. Details of the counterparties to the agreement (including name and relationship with the listed entity) iii. Date of entering into the Agreement	The SPA has been entered into among the SPA Parties. The SPA Letter Agreement has also been executed among the (same) SPA Parties. Other details required as per 2(i) and 2(ii) are the same as set out in the disclosure dated December 15, 2025 regarding the execution of the SPA. The SPA Letter Agreement has been executed on January 22, 2026.
3.	Purpose of entering into the agreement	Refer to paragraph 12 below.
4.	Shareholding, if any, in the entity with whom the agreement is executed	The Sellers do not hold any shares in the Purchasers and vice versa.
5.	Significant terms of the agreement (in brief), including special rights to appoint directors, first right to share subscription in case of	Refer to paragraph 12 below.

	issuance of shares, right to restrict any change in capital structure, etc.	
6.	Extent and the nature of impact on management or control of the listed entity	Refer to paragraph 12 below.
7.	Details and quantification of the restriction or liability imposed upon the listed entity	The SPA Letter Agreement does not impose any additional restrictions/ qualifications on the Company, other than as disclosed in the Company's disclosure dated December 15, 2025 and as set out in paragraph 12 below.
8.	Whether the said parties are related to promoter / promoter group / group companies in any manner. If yes, nature of relationship	As on the date of execution of the SPA Letter Agreement, the Sellers are members of the promoter/ promoter group of the Company. As on the date of execution of the SPA Letter Agreement, none of the Purchasers form part of the promoter/ promoter group/ group companies of the Company and are not related to the promoter/promoter group/group companies of the Company.
9.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	No, the aforesaid transaction is not a related party transaction.
10.	In case of issuance of shares to the parties, details of issue price, class of shares issued.	Not applicable, as there are no shares being issued as part of the transaction.
11.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	No disclosures, other than as disclosed in the Company's disclosure dated December 15, 2025.
12.	In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement. ii. nature of the agreement. iii. date of execution of the agreement. iv. details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier). v. reasons for rescission and impact thereof (including impact on management or	i. The SPA Letter Agreement has been executed between the SPA Parties. ii. The SPA Letter Agreement is in the nature of an amendment to the SPA. iii. The SPA Letter Agreement is executed on January 22, 2026. iv. Pursuant to the SPA Letter Agreement, the Parties have agreed that the date of completion of the transfer of 1,63,00,230 equity shares, representing 50.80% of the total paid

<p>control and on the restriction or liability quantified earlier).</p>	<p>up equity share capital of the Company, is January 23, 2026 ("Identified Closing Date").</p> <p>Accordingly, on and from the completion of such transfer on the Identified Closing Date, the Sellers will cease to be in control of the Company and will accordingly be de-classified from being a member of the promoter/ promoter group of the Company, in accordance with Regulation 31A(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</p> <p>v. Not applicable, as the SPA has not been rescinded.</p>
---	---